Tourette Syndrome (TS) – Epidemiology Insights and Forecast Report – 2020 To 2040

Tourette Syndrome (TS) Epidemiology Insights

Thelansis’s “⁠Tourette Syndrome (TS) Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.

Tourette Syndrome (TS) Overview

Tourette syndrome (TS) is a complex neurodevelopmental disorder clinically defined by the presence of multiple motor tics and at least one vocal (phonic) tic that persist and fluctuate in severity for more than a year, with an onset prior to age 18. The underlying pathophysiology is strongly linked to dopamine dysregulation within the cortico-striato-thalamo-cortical (CSTC) circuitry. TS falls under the broader spectrum of tic disorders, which modern diagnostic frameworks classify alongside Provisional Tic Disorder (lasting less than a year) and Persistent Motor or Vocal Tic Disorder. Clinically, TS follows a classic waxing and waning course, typically peaking during early adolescence, and is highly associated with neurobehavioral comorbidities, most notably ADHD and OCD. Because there are currently no disease-modifying therapies to cure the root neurological dysfunction, management is strictly symptom-directed; the modern standard of care prioritizes Comprehensive Behavioral Intervention for Tics (CBIT), strategically escalating to targeted pharmacotherapy—such as alpha-2 adrenergic agonists, dopamine antagonists, or VMAT2 inhibitors—only when tics cause profound physical discomfort or significantly disrupt psychosocial functioning.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
• Global findings
• G8 findings
• Regional findings
• Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

Read more: Tourette Syndrome (TS) – Epidemiology Insights and Forecast Report – 2020 To 2040